Table 3

Characteristics of patients with preserved and impaired LV function and intensity of immunostaining for GLP-1 and GLP-1 receptor

Gender	Age	LVEDD	LVEF	BNP	Diagnosis	Intensity of immunostaining
Gender	Age	LVEDD	LVEF	BNP	Diagnosis	GLP-1	GLP-1 receptor
Preserved LVEF (≥55%)
Male	35	44	73	72	HCM	1+	2+
Male	63	55	68	60	HCM	1+	2+
Male	51	48	58	7	Post-MC	1+	2+
Male	77	37	75	33	Post-MC	1+	2+
Male	46	44	73	18	Idiopathic VT	1+	1+
Male	63	52	76	33	HCM	1+	1+
Impaired LVEF (<55%)
Male	70	72	24	241	DCM	1+	2+
Male	70	55	25	4250	DCM	1+	3+
Male	48	61	37	307	DCM	1+	3+
Female	33	66	27	758	PPCM	1+	4+
Male	53	61	30	78	DCM	1+	5+
Male	31	51	34	38	Post–MC	1+	2+

BNP, brain natriuretic peptide; DCM, dilated cardiomyopathy; GLP-1, glucagon-like peptide-1; HCM, hypertrophic cardiomyopathy; LVEF, left ventricular ejection fraction; MC, myocarditis; PPCM, peripartum cardiomyopathy; VT, ventricular tachycardia.